| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of*
Gastroenterology, Hepatology, and Endocrinology, and Visceral and Transplant Surgery, Medical School of Hannover, Hannover, Germany and Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany
In synergy with stem cell factor (SCF), IL-4 strongly enhances mast cell proliferation and shifts IgE-dependent cytokine production in mature human mast cells toward an increased release of Th2 cytokines such as IL-3, IL-5, and IL-13 and a decreased IL-6 expression. In this study we analyzed the kinetics and the mechanisms of these IL-4 effects on mast cells purified from intestinal tissue. If the cells were first cultured with IL-4 for 14 days and then without IL-4 for another 14 days, mast cells lost the capacity of producing higher amounts of Th2 cytokines and regained the capacity of producing IL-6. The IL-4-induced up-regulation of mast cell proliferation and Fc
RI expression was also reversible if IL-4 was withdrawn for 14 days. Interestingly, in contrast to IL-4, proliferation and phenotype of human intestinal mast cells were not affected by IL-13 although both cytokines were capable of inducing STAT6 activation. Instead, IL-4 treatment (but not IL-13 treatment) was associated with an increased activity of ERK1/2 and c-Fos, the downstream target of ERK1/2 and component of the transcription factor AP-1. Consistently, mast cell proliferation and cytokine expression in response to IL-4 was blocked by the MEK inhibitor PD98059. In summary, our data show that the IL-4 effects on human intestinal mast cell functions are reversible and accompanied by an increased activity of ERK1/2 and c-Fos.
This article has been cited by other articles:
|
|
 |
|
  K. Speiran, D. P. Bailey, J. Fernando, M. Macey, B. Barnstein, M. Kolawole, D. Curley, S. S. Watowich, P. J. Murray, C. Oskeritzian, et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10 J. Leukoc. Biol., May 1, 2009; 85(5): 826 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kramer, G. Sellge, A. Lorentz, D. Krueger, M. Schemann, K. Feilhauer, F. Gunzer, and S. C. Bischoff Selective Activation of Human Intestinal Mast Cells by Escherichia coli Hemolysin J. Immunol., July 15, 2008; 181(2): 1438 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Forbes, K. Groschwitz, J. P. Abonia, E. B. Brandt, E. Cohen, C. Blanchard, R. Ahrens, L. Seidu, A. McKenzie, R. Strait, et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity J. Exp. Med., April 14, 2008; 205(4): 897 - 913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Katsoulotos, M. Qi, J. C. Qi, K. Tanaka, W. E. Hughes, T. J. Molloy, R. Adachi, R. L. Stevens, and S. A. Krilis The Diacylglycerol-dependent Translocation of Ras Guanine Nucleotide-releasing Protein 4 inside a Human Mast Cell Line Results in Substantial Phenotypic Changes, Including Expression of Interleukin 13 Receptor {alpha}2 J. Biol. Chem., January 18, 2008; 283(3): 1610 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Jiang, Y. Kanaoka, C. Feng, K. Nocka, S. Rao, and J. A. Boyce Cutting edge: interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling. J. Immunol., September 1, 2006; 177(5): 2755 - 2759. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
